Navigation Links
Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
Date:3/28/2008

- Company Plans to Request Timely Hearing before a NASDAQ Listing

Qualifications Panel -

FREMONT, Calif., March 28 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML, VRMLD) (the "Company"), a molecular diagnostics company, announced today that on March 18, 2008, the Company received communication from The NASDAQ Stock Market ("NASDAQ") that, as a result of the Company's common stock closing at $1.00 per share or more for a minimum of 10 consecutive business days, it has achieved compliance with the minimum bid price requirement for continued listing set forth in NASDAQ Marketplace Rule 4310(c)(4) ("Rule 4310(c)(4)").

The communication follows a notice of noncompliance from NASDAQ dated September 6, 2007, which was disclosed by the Company on September 7, 2007, that indicated that the Company failed to comply with the minimum bid price requirement for continued listing set forth in Rule 4310(c)(4). The notice of noncompliance gave the Company notice that the bid price of its common stock had closed under $1.00 per share for the previous 30 business days, and stated that if the Company could not demonstrate compliance with Rule 4310(c)(4) by March 4, 2008, the NASDAQ staff would determine whether or not the Company meets The NASDAQ Capital Market initial listing criteria set forth in NASDAQ Marketplace Rule 4310(c), except for the bid price requirement.

The bid price requirement was met in part as a result of the 1-for-10 reverse stock split of the Company's outstanding common stock effected by the filing of the Company's Third Amended and Restated Certificate of Incorporation on February 29, 2008, which was disclosed by the Company on March 3, 2008. The reverse stock split was effective with respect to stockholders of record upon the close of business on March 3, 2008.

The common stock has been traded on the NASDAQ Capital Market under the symbol "VRMLD" beginning on March 4, 2008, to designate that it is trading on a post-reverse-split basis, and will resume trading under the symbol "VRML" on April 2, 2008.

The Company also announced today that, on March 25, 2008, the Company received a letter from the Listing Qualifications Staff of NASDAQ (the "Staff Determination") notifying the Company that, based upon the Company's non-compliance with the $35 million market value of listed securities requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Marketplace Rule 4310(c)(3)(B), the Company's securities are subject to delisting from NASDAQ unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (the "NASDAQ Panel").

The Company plans to timely request a hearing before a NASDAQ Panel, which will stay any action with respect to the Staff Determination until such NASDAQ Panel renders a decision subsequent to the hearing. The Company anticipates that the hearing will be scheduled to occur within the next 45 days. There can be no assurance that such NASDAQ Panel will grant the Company's request for continued listing.

The Staff Determination follows correspondence from NASDAQ dated February 22, 2008, which was disclosed by the Company on February 27, 2008, that, should the Company fail to regain compliance with the market value of listed securities requirement by March 24, 2008, NASDAQ would provide written notification of such and the opportunity to request a hearing before the NASDAQ Panel.

The Company also announced today that that in its 2007 financial statements to be included in the Company's Annual Report on Form 10-K, which the Company expects will be filed on March 31, 2008, the audit opinion of PriceWaterhouseCoopers LLP will contain a "going concern" qualification. NASDAQ's marketplace rules require NASDAQ-listed companies to publicly announce the receipt of an audit opinion containing a "going concern" qualification.

The Company's Annual Report on Form 10-K will be available from the U.S. Securities and Exchange Commission's website at http://www.sec.gov or the "Investor Information" section of the Company's Web site at http://www.vermillion.com.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, hematology, cardiology and women's health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions and the risks and uncertainties discussed in Vermillion's latest Form 10-K and Vermillion's periodic reports on Form 10-Q and Form 8-K. These forward-looking statements are based on Vermillion's current expectations. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Forward-looking statements cannot be guaranteed and actual results may differ materially from Vermillion's current expectations. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology:
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):